Zhejiang Hisoar Pharmaceutical Co Ltd

Zhejiang Hisoar Pharmaceutical Co., Ltd. announced that its wholly owned subsidiary Zhejiang Hisoar Chuannan Pharmaceutical Co., Ltd. has received the Chemical API Marketing Authorization Approval Notice for adenosine cyclophosphate issued by the National Medical Products Administration, with registration number Y20240000147. Adenosine cyclophosphate is a vasodilator used to treat angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock, and it also has therapeutic effects on acute leukemia. According to data from Menet, sales of adenosine cyclophosphate for injection in China's urban public hospitals reached 305.84 million yuan in 2025. The company stated that approval of this API will enrich its specialty API product pipeline, optimize its industrial layout, and enhance overall competitiveness, but domestic production and sales can only begin after passing GMP compliance inspection. It will not have a significant impact on performance in the short term, and the timing and specific sales situation remain uncertain.

Hisoar Pharmaceutical's wholly owned subsidiary Zhejiang Hisoar Chuannan Pharmaceutical recently received the renewed Veterinary Drug Production License and Veterinary Drug GMP Certificate from the Zhejiang Provincial Department of Agriculture and Rural Affairs. The production scope covers non-sterile active pharmaceutical ingredients, including florfenicol with two production lines and flunixin meglumine, with validity until May 17, 2027. The company stated that the acceptance and renewal of certificates for the newly built and expanded florfenicol API production line mark the line's entry into commercial operation. This will further expand florfenicol production capacity reserves, enable rapid response to market supply and demand changes, and continuously strengthen core competitiveness. The company also noted that drug production and sales are subject to industry policies, market conditions, and other factors, and there are uncertainties.